Is Sarolaner (Simparica) safe for dogs and cats?
Moderate risk for petsSarolaner presents a moderate risk to dogs due to the isoxazoline class FDA neurological adverse event warning (tremors, ataxia, seizures documented in post-marketing surveillance). In most dogs, Simparica/Simparica TRIO is well-tolerated and provides excellent comprehensive monthly parasite protection. Dogs with pre-existing epilepsy or seizure disorders face higher risk and should only receive isoxazolines with informed owner consent and close monitoring. For Simparica TRIO, the milbemycin component also triggers MDR1/ABCB1 breed caution — herding breeds with confirmed MDR1 −/− status should be assessed carefully; at the milbemycin dose in TRIO (0.5 mg/kg), the safety margin is generally adequate for MDR1 +/− heterozygotes but homozygous dogs may be at risk. The 11–12-day half-life means adverse events may persist for 2–3 weeks after dosing.
What is sarolaner (simparica)?
The IUPAC name is 1-[6-[(5S)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]spiro[1H-2-benzofuran-3,3'-azetidine]-1'-yl]-2-methylsulfonylethanone.
Also known as: 1-[6-[(5S)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]spiro[1H-2-benzofuran-3,3'-azetidine]-1'-yl]-2-methylsulfonylethanone, Sarolaner, Simparica, PF-6450567.
- IUPAC name
- 1-[6-[(5S)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]spiro[1H-2-benzofuran-3,3'-azetidine]-1'-yl]-2-methylsulfonylethanone
- CAS number
- 1398609-39-6
- Molecular formula
- C23H18Cl2F4N2O5S
- Molecular weight
- 581.4 g/mol
- SMILES
- CS(=O)(=O)CC(=O)N1CC2(C1)C3=C(CO2)C=C(C=C3)C4=NOC(C4)(C5=CC(=C(C(=C5)Cl)F)Cl)C(F)(F)F
- PubChem CID
- 73169092
Risk for dogs
Moderate riskSarolaner presents a moderate risk to dogs due to the isoxazoline class FDA neurological adverse event warning (tremors, ataxia, seizures documented in post-marketing surveillance). In most dogs, Simparica/Simparica TRIO is well-tolerated and provides excellent comprehensive monthly parasite protection. Dogs with pre-existing epilepsy or seizure disorders face higher risk and should only receive isoxazolines with informed owner consent and close monitoring. For Simparica TRIO, the milbemycin component also triggers MDR1/ABCB1 breed caution — herding breeds with confirmed MDR1 −/− status should be assessed carefully; at the milbemycin dose in TRIO (0.5 mg/kg), the safety margin is generally adequate for MDR1 +/− heterozygotes but homozygous dogs may be at risk. The 11–12-day half-life means adverse events may persist for 2–3 weeks after dosing.
Regulatory consensus
1 regulatory bodyhas classified Sarolaner (Simparica).
| Agency | Year | Classification | Notes |
|---|---|---|---|
| IARC | 2022 | Not evaluated by IARC — sarolaner (Simparica, Simparica TRIO; Zoetis) is an FDA/CVM-approved isoxazoline ectoparasiticide for dogs; monthly oral tablet providing flea and tick protection; FDA 2018/2022 class-wide neurological adverse event warning; Simparica TRIO combines sarolaner with milbemycin oxime and pyrantel; no carcinogenicity classification |
Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.
Where pets encounter sarolaner (simparica)
- Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
- Occupational Environments — Factories, Warehouses, Transportation vehicles
Safer alternatives
Lower-risk approaches that achieve a similar outcome to Sarolaner (Simparica):
-
Alternative drug class; Non-pharmacological therapy; Lowest effective dose
Trade-offs: Direct chemical substitution requires verification that the replacement does not introduce new hazards (regrettable substitution). Conduct full hazard assessment of proposed alternative before adoption.Relative cost: 1.2-2×
Frequently asked questions
Is sarolaner (simparica) safe for pets?
Sarolaner presents a moderate risk to dogs due to the isoxazoline class FDA neurological adverse event warning (tremors, ataxia, seizures documented in post-marketing surveillance). In most dogs, Simparica/Simparica TRIO is well-tolerated and provides excellent comprehensive monthly parasite protection. Dogs with pre-existing epilepsy or seizure disorders face higher risk and should only receive isoxazolines with informed owner consent and close monitoring. For Simparica TRIO, the milbemycin component also triggers MDR1/ABCB1 breed caution — herding breeds with confirmed MDR1 −/− status should be assessed carefully; at the milbemycin dose in TRIO (0.5 mg/kg), the safety margin is generally adequate for MDR1 +/− heterozygotes but homozygous dogs may be at risk. The 11–12-day half-life means adverse events may persist for 2–3 weeks after dosing.
What products contain sarolaner (simparica)?
Sarolaner (Simparica) appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).
See Sarolaner (Simparica) in the pets app
Look up products containing sarolaner (simparica), compare to alternatives, and explore the full data record.
Open in pets View raw API dataSources (1)
- Sarolaner Simparica Simparica TRIO Zoetis FDA CVM 2016; Isoxazoline GluCl GABA Channel Dog; Triple Combination Milbemycin Oxime Pyrantel Heartworm Flea Tick; FDA 2018 2022 Class Warning Neurological Tremors Ataxia Seizures; Half-Life 11-12 Days 99.9% Protein Binding; MDR1 Milbemycin Component TRIO; EMA VMP Environmental Risk Aquatic Arthropod; Simparica TRIO Comprehensive Monthly Prevention; IARC Not Evaluated (2022) — regulatory
Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →